Shares of MacroGenics Inc (NASDAQ:MGNX) have been given a consensus rating of “Buy” by the fourteen analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $33.42.

Several brokerages recently weighed in on MGNX. ValuEngine lowered shares of MacroGenics from a “buy” rating to a “hold” rating in a research report on Monday, May 13th. Credit Suisse Group began coverage on shares of MacroGenics in a research report on Wednesday, April 17th. They set an “outperform” rating and a $29.00 price objective on the stock. Cowen reaffirmed a “buy” rating on shares of MacroGenics in a research report on Thursday, May 2nd. BidaskClub raised shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 4th. Finally, Guggenheim began coverage on shares of MacroGenics in a research report on Friday, April 12th. They set a “neutral” rating on the stock.

In other MacroGenics news, SVP Eric Blasius Risser sold 3,000 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $18.38, for a total transaction of $55,140.00. Following the transaction, the senior vice president now owns 33,806 shares in the company, valued at $621,354.28. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 7.88% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. OppenheimerFunds Inc. grew its holdings in MacroGenics by 0.4% during the first quarter. OppenheimerFunds Inc. now owns 4,463,410 shares of the biopharmaceutical company’s stock valued at $80,252,000 after purchasing an additional 16,569 shares during the last quarter. BlackRock Inc. grew its holdings in MacroGenics by 5.5% during the fourth quarter. BlackRock Inc. now owns 3,401,391 shares of the biopharmaceutical company’s stock valued at $43,198,000 after purchasing an additional 176,135 shares during the last quarter. BB Biotech AG grew its holdings in MacroGenics by 9.8% during the fourth quarter. BB Biotech AG now owns 3,283,272 shares of the biopharmaceutical company’s stock valued at $41,698,000 after purchasing an additional 292,860 shares during the last quarter. Vanguard Group Inc. grew its holdings in MacroGenics by 7.9% during the third quarter. Vanguard Group Inc. now owns 2,270,541 shares of the biopharmaceutical company’s stock valued at $48,680,000 after purchasing an additional 165,937 shares during the last quarter. Finally, Wasatch Advisors Inc. grew its holdings in MacroGenics by 23.6% during the first quarter. Wasatch Advisors Inc. now owns 1,291,513 shares of the biopharmaceutical company’s stock valued at $23,221,000 after purchasing an additional 246,536 shares during the last quarter. Institutional investors own 90.64% of the company’s stock.

Shares of MGNX opened at $18.34 on Thursday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 6.47 and a current ratio of 6.47. MacroGenics has a twelve month low of $9.87 and a twelve month high of $32.32.

MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.95) by ($0.04). The business had revenue of $9.66 million for the quarter, compared to the consensus estimate of $11.46 million. MacroGenics had a negative net margin of 256.47% and a negative return on equity of 57.65%. On average, equities analysts expect that MacroGenics will post -3.7 earnings per share for the current fiscal year.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.

See Also: What is a balanced fund?

Analyst Recommendations for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.